company background image
2160

MicroPort CardioFlow Medtech SEHK:2160 Stock Report

Last Price

HK$3.43

Market Cap

HK$8.3b

7D

22.1%

1Y

-79.2%

Updated

25 Jun, 2022

Data

Company Financials +
2160 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

2160 Stock Overview

MicroPort CardioFlow Medtech Corporation, a medical device company, researches, develops, and commercializes transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China.

MicroPort CardioFlow Medtech Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for MicroPort CardioFlow Medtech
Historical stock prices
Current Share PriceHK$3.43
52 Week HighHK$16.80
52 Week LowHK$2.05
Beta0
1 Month Change60.28%
3 Month Change32.95%
1 Year Change-79.19%
3 Year Changen/a
5 Year Changen/a
Change since IPO-81.77%

Recent News & Updates

Apr 04
Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts

Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts

Market forces rained on the parade of MicroPort CardioFlow Medtech Corporation ( HKG:2160 ) shareholders today, when...

Shareholder Returns

2160HK Medical EquipmentHK Market
7D22.1%15.2%2.1%
1Y-79.2%-60.3%-23.3%

Return vs Industry: 2160 underperformed the Hong Kong Medical Equipment industry which returned -60.3% over the past year.

Return vs Market: 2160 underperformed the Hong Kong Market which returned -23.3% over the past year.

Price Volatility

Is 2160's price volatile compared to industry and market?
2160 volatility
2160 Average Weekly Movement10.5%
Medical Equipment Industry Average Movement8.4%
Market Average Movement7.0%
10% most volatile stocks in HK Market13.8%
10% least volatile stocks in HK Market3.3%

Stable Share Price: 2160 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 2160's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
2010451Guoming Chenhttps://www.cardioflowmedtech.com

MicroPort CardioFlow Medtech Corporation, a medical device company, researches, develops, and commercializes transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China. It offers Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set to target aortic, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company was founded in 2010 and is headquartered in Shanghai, China.

MicroPort CardioFlow Medtech Fundamentals Summary

How do MicroPort CardioFlow Medtech's earnings and revenue compare to its market cap?
2160 fundamental statistics
Market CapCN¥7.03b
Earnings (TTM)-CN¥183.26m
Revenue (TTM)CN¥200.81m

35.0x

P/S Ratio

-38.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2160 income statement (TTM)
RevenueCN¥200.81m
Cost of RevenueCN¥82.11m
Gross ProfitCN¥118.70m
Other ExpensesCN¥301.97m
Earnings-CN¥183.26m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.076
Gross Margin59.11%
Net Profit Margin-91.26%
Debt/Equity Ratio0%

How did 2160 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 2160 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2160?

Other financial metrics that can be useful for relative valuation.

2160 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue24.1x
Enterprise Value/EBITDA-27.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 2160's PS Ratio compare to its peers?

2160 PS Ratio vs Peers
The above table shows the PS ratio for 2160 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average14x

Price-To-Sales vs Peers: 2160 is expensive based on its Price-To-Sales Ratio (35x) compared to the peer average (14x).


Price to Earnings Ratio vs Industry

How does 2160's PE Ratio compare vs other companies in the Hong Kong Medical Equipment Industry?

Price-To-Sales vs Industry: 2160 is expensive based on its Price-To-Sales Ratio (35x) compared to the Hong Kong Medical Equipment industry average (6.2x)


Price to Sales Ratio vs Fair Ratio

What is 2160's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2160 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio35x
Fair PS Ratio10.5x

Price-To-Sales vs Fair Ratio: 2160 is expensive based on its Price-To-Sales Ratio (35x) compared to the estimated Fair Price-To-Sales Ratio (10.5x).


Share Price vs Fair Value

What is the Fair Price of 2160 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2160 (HK$3.43) is trading below our estimate of fair value (HK$13.35)

Significantly Below Fair Value: 2160 is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2160's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is MicroPort CardioFlow Medtech forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


39.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2160 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2160 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2160 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2160's revenue (36.7% per year) is forecast to grow faster than the Hong Kong market (10.2% per year).

High Growth Revenue: 2160's revenue (36.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2160 is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has MicroPort CardioFlow Medtech performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


54.0%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: 2160 is currently unprofitable.

Growing Profit Margin: 2160 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 2160's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 2160's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2160 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (35.4%).


Return on Equity

High ROE: 2160 has a negative Return on Equity (-5.92%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is MicroPort CardioFlow Medtech's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 2160's short term assets (CN¥2.6B) exceed its short term liabilities (CN¥164.4M).

Long Term Liabilities: 2160's short term assets (CN¥2.6B) exceed its long term liabilities (CN¥101.1M).


Debt to Equity History and Analysis

Debt Level: 2160 is debt free.

Reducing Debt: 2160 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2160 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 2160 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is MicroPort CardioFlow Medtech current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2160's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2160's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2160's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2160's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 2160 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Guoming Chen (36 yo)

1.75yrs

Tenure

Mr. Guoming Chen serves as Executive Director and President of MicroPort CardioFlow Medtech Corporation since September 29, 2020. Mr. Chen serves as a Director and General Manager of MP CardioFlow on Septe...


Leadership Team

Experienced Management: 2160's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: 2160's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

MicroPort CardioFlow Medtech Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: MicroPort CardioFlow Medtech Corporation
  • Ticker: 2160
  • Exchange: SEHK
  • Founded: 2010
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: HK$8.252b
  • Shares outstanding: 2.41b
  • Website: https://www.cardioflowmedtech.com

Number of Employees


Location

  • MicroPort CardioFlow Medtech Corporation
  • Zhangjiang Hi-Tech Park
  • No. 1601 Zhangdong Road
  • Shanghai
  • 201203
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/25 00:00
End of Day Share Price2022/06/24 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.